CGTX News and Press, Cognition Therapeutics Inc. From 08/05/22

An analysis of biomarker data from Cognition Therapeutics' ( NASDAQ: CGTX ) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses...

Hyzon Motors ( HYZN ) -36% after disclosing operational inefficiencies, financial issues . Helius Medical Technologies ( HSDT ) -30% . Quoin Pharmaceuticals ( QNRX ) -23% . Chembio Diagnostics ( CEMI ) -18% on Q2 earnings release . ...

NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) announced that Mary Hamby, Ph.D. , vice president of research, presented results at the at Alzheimer’s Association International Conference (AAIC) of proteomic analysi...

PURCHASE, N.Y., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

- Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes - NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) will be in attendance at the 2022 Alzheimer’s Association International Conference (...

Gainers: Allena Pharmaceuticals ( ALNA ) +191% . Brickell Biotech ( BBI ) +78% . Decibel Therapeutics ( DBTX ) +35% . Cognition Therapeutics ( CGTX ) +26% . Akouos ( AKUS ) +20% . Fujian Blue Hat Interactive Entertainment Tec...

Cognition Therapeutics (NASDAQ:CGTX) stock rose ~6% on June 23 after the company said the first patient was dosed in a phase 2 trial of oral drug CT1812 to treat patients with dementia with Lewy bodies (DLB). The company plans to enroll 120 adults between 50 and 80 years of age with a DL...

- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association - NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (Nasdaq: CGTX) today...

PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi , Cognition’s president and CEO will be presenting an update o...